RxDoctor Payments DataLook up a doctor →

Harry McDaris, MD

Neurology · Huntsville, ALNPI 1265499099

Payments from drug & device makers

$306,686in general payments, 2019–2025

Across 1,124 payments — averaging $272.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$128K
  • Lilly USA, LLC$63K
  • Amgen$55K
  • Pfizer$17K
  • Teva Pharmaceuticals USA, Inc.$16K
  • Biohaven Pharmaceuticals, Inc.$14K
  • plus $15K from 15 others

What the payments were for

  • Consulting fees$8,3993%
  • Speaking & faculty fees$274,79090%
  • Grants$440%
  • Travel & lodging$9,4773%
  • Food & beverage$13,7994%
  • Education$1780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$306,686 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$160,829
Medicare patients
171
Services billed
24,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm118$87,434
Nurtec OdtRimegepant Sulfate36$48,849
Aimovig AutoinjectorErenumab-Aooe62$45,390
UbrelvyUbrogepant22$41,920
QuliptaAtogepant27$26,380
Zembrace SymtouchSumatriptan Succinate21$22,748
Sumatriptan Succinate266$17,772
Topiramate ErTopiramate12$12,585
Ajovy AutoinjectorFremanezumab-Vfrm13$10,515
Eletriptan HbrEletriptan Hydrobromide43$8,716
Tizanidine Hcl155$5,661
Topiramate433$4,869
RizatriptanRizatriptan Benzoate155$4,450
Pregabalin71$3,672
Amitriptyline Hcl222$3,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$127,750$68,30149 claims
PfizerNurtec Odt$16,503$48,84936 claims
Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate$534$27,617454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 neurology providers in Alabama.

Other neurology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →